Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension
Hossein A. Ghofrani, MD*,*,
Joanna Pepke-Zaba, MD ,
Joan A. Barbera, MD ,
Richard Channick, MD ,
Anne M. Keogh, MD||,
Miguel A. Gomez-Sanchez, MD¶,
Meinhard Kneussl, MD and
Friedrich Grimminger, MD*
* Department of Internal Medicine Pulmonary Hypertension Center, University Hospital, Giessen, Germany
Pulmonary Vascular Disease Unit, Papworth Hospital, Papworth Everard, Cambridge, United Kingdom
Servei de Pneumologia i Al.lèrgia Respiratòria, Unitat de Transplantament Renal, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain
Division of Pulmonary and Critical Care Medicine, University of California, San Diego, California, USA
|| Xavier 4, St. Vincent's Hospital, Darlinghurst, Australia
¶ Unidad de Insuficiencia Cardíaca e Hipertensión Pulmonar, Servicio de Cardiología, Hospital Universitario 12 de Octubre, Madrid, Spain
Department of Internal Medicine V, University Hospital, Vienna, Austria
Manuscript received December 1, 2003;
revised manuscript received February 6, 2004,
accepted February 10, 2004.
*
Reprint requests and correspondence: Dr. Hossein-Ardeschir Ghofrani, Department of Internal Medicine, Pulmonary Hypertension Center, University Hospital, Klinikstrasse 36, 35392 Giessen, Germany.
ardeschir.ghofrani{at}innere.med.uni-giessen.de
Pulmonary hypertension (PH) is a disease of various origins. Nitric oxide—a potent vasodilator—is a key player of pulmonary vasoregulation. Nitric oxide signaling is mainly mediated by the guanylate cyclase/cyclic guanylate monophosphate pathway. The effects of this second messenger system are limited by enzymatic degradation through phosphodiesterases (PDEs). Recently, beneficial effects of the oral PDE-5 inhibitor sildenafil (originally approved for the treatment of erectile dysfunction) were reported for the treatment of PH. We provide a brief overview of the experimental and clinical application of PDE inhibitors in the field of PH. In particular, studies reporting the clinical effectiveness of sildenafil are highlighted. This agent, despite oral application, displays characteristics of a pulmonary selective vasodilator. In addition, evidence shows that sildenafil is operative mainly in the vasculature of well-ventilated areas of the lung. However, to date, controlled randomized trials proving the efficacy of this approach for the treatment of pulmonary arterial hypertension are lacking. The results of such studies have to confirm the current encouraging findings before recommendations regarding the use of PDE-5 inhibitors as a new treatment for PH can be made.
|
Abbreviations and Acronyms
| | cAMP | = cyclic adenylate monophosphate | | cGMP | = cyclic guanylate monophosphate | | GC | = guanylate cyclase | | HIV | = human immunodeficiency virus | | NO | = nitric oxide | | NYHA | = New York Heart Association | | PAH | = pulmonary arterial hypertension | | PDE | = phosphodiesterase | | PH | = pulmonary hypertension | | PPH | = primary pulmonary hypertension |
|
This article has been cited by other articles:
|
|
|
|
 
I. Diebold, T. Djordjevic, A. Petry, A. Hatzelmann, H. Tenor, J. Hess, and A. Gorlach
Phosphodiesterase 2 Mediates Redox-Sensitive Endothelial Cell Proliferation and Angiogenesis by Thrombin via Rac1 and NADPH Oxidase 2
Circ. Res.,
May 22, 2009;
104(10):
1169 - 1177.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Baliga, L. Zhao, M. Madhani, B. Lopez-Torondel, C. Visintin, D. Selwood, M. R. Wilkins, R. J. MacAllister, and A. J. Hobbs
Synergy between Natriuretic Peptides and Phosphodiesterase 5 Inhibitors Ameliorates Pulmonary Arterial Hypertension
Am. J. Respir. Crit. Care Med.,
October 15, 2008;
178(8):
861 - 869.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. T. Schermuly, J-P. Stasch, S. S. Pullamsetti, R. Middendorff, D. Muller, K-D. Schluter, A. Dingendorf, S. Hackemack, E. Kolosionek, C. Kaulen, et al.
Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension
Eur. Respir. J.,
October 1, 2008;
32(4):
881 - 891.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. T.-J. Gan, S. Holverda, J. T. Marcus, W. J. Paulus, K. M. Marques, J. G.F. Bronzwaer, J. W. Twisk, A. Boonstra, P. E. Postmus, and A. Vonk-Noordegraaf
Right Ventricular Diastolic Dysfunction and the Acute Effects of Sildenafil in Pulmonary Hypertension Patients
Chest,
July 1, 2007;
132(1):
11 - 17.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. McMurtry, R. Moudgil, K. Hashimoto, S. Bonnet, E. D. Michelakis, and S. L. Archer
Overexpression of human bone morphogenetic protein receptor 2 does not ameliorate monocrotaline pulmonary arterial hypertension
Am J Physiol Lung Cell Mol Physiol,
April 1, 2007;
292(4):
L872 - L878.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. D. Fell and F. J. Martinez
The Impact of Pulmonary Arterial Hypertension on Idiopathic Pulmonary Fibrosis
Chest,
March 1, 2007;
131(3):
641 - 643.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. K. Shim, Y. S. Choi, Y. J. Oh, D. H. Kim, Y. W. Hong, and Y. L. Kwak
Effect of oral sildenafil citrate on intraoperative hemodynamics in patients with pulmonary hypertension undergoing valvular heart surgery
J. Thorac. Cardiovasc. Surg.,
December 1, 2006;
132(6):
1420 - 1425.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Collins, B. Bastian, L. Quiqueree, C. Jones, R. Morgan, and G. Reeves
Abnormal pulmonary vascular responses in patients registered with a systemic autoimmunity database: Pulmonary Hypertension Assessment and Screening Evaluation using stress echocardiography (PHASE-I)
Eur J Echocardiogr,
December 1, 2006;
7(6):
439 - 446.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Bresser, J. Pepke-Zaba, X. Jais, M. Humbert, and M. M. Hoeper
Medical Therapies for Chronic Thromboembolic Pulmonary Hypertension: An Evolving Treatment Paradigm
Proceedings of the ATS,
September 1, 2006;
3(7):
594 - 600.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. M. Tsai, M. W. Turrentine, B. C. Sheridan, M. Wang, A. C. Fiore, J. W. Brown, and D. R. Meldrum
Differential Effects of Phosphodiesterase-5 Inhibitors on Hypoxic Pulmonary Vasoconstriction and Pulmonary Artery Cytokine Expression
Ann. Thorac. Surg.,
January 1, 2006;
81(1):
272 - 278.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Galie, H. A. Ghofrani, A. Torbicki, R. J. Barst, L. J. Rubin, D. Badesch, T. Fleming, T. Parpia, G. Burgess, A. Branzi, et al.
Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension
N. Engl. J. Med.,
November 17, 2005;
353(20):
2148 - 2157.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Weitzenblum and A. Chaouat
Severe Pulmonary Hypertension in COPD: Is It a Distinct Disease?
Chest,
May 1, 2005;
127(5):
1480 - 1482.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Col. K. C. Quirolo
Resources aid in management of sickle cell disease
AAP News,
October 1, 2004;
25(4):
190 - 191.
[Full Text]
[PDF]
|
|
|
|
